

## WEST Search History





DATE: Wednesday, March 31, 2004

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L19	L18 and (actinomycin\$ or dactinomycin or (WI 53233) or Cosmegen)	29
<input type="checkbox"/>	L18	L17 and (EDDA or EDTA or IDA or NTA or EDMA)	38
<input type="checkbox"/>	L17	L16 and catheter	64
<input type="checkbox"/>	L16	L15 and (percutaneous\$ or transdermal\$)	66
<input type="checkbox"/>	L15	L14 and (permeation enhanc\$)	89
<input type="checkbox"/>	L14	L13 and endothelia\$	92
<input type="checkbox"/>	L13	L12 and (balloon or infusion)	101
<input type="checkbox"/>	L12	L11 and (polycaprolact\$ or polysiloxane? or (ethylene vinyl alcohol) or polyhydroxyvaler\$ polyact\$ or polydroxybutyr\$ or polydioxanone)	106
<input type="checkbox"/>	L11	L10 and (morpholinostyrene or (acetyl penicillamine) or VEGF or (endothelial growth factor))	111
<input type="checkbox"/>	L10	L9 and ((hydrolyzed triglyceride?) or (fatty acid suga) or olei\$ or histamine? bradykinin\$ or (TNF alpha) or (tumor necrosis factor alpha) nitroglycerine or (sodium nitroprusside) or (diethylamine sodium))	111
<input type="checkbox"/>	L9	L8 and ((membrane junctions) or (cell membrane?))	111
<input type="checkbox"/>	L8	L7 and expand\$	113
<input type="checkbox"/>	L7	L6 and (drug delivery)	163
<input type="checkbox"/>	L6	L5 and ((pluronic p 85) or verapamil or disulfiram or (antisense oligonucleotide?))	165
<input type="checkbox"/>	L5	L4 and (p glycoprotein) and blocker	169
<input type="checkbox"/>	L4	L3 and (iminodiacet\$ or nitriloacet\$ or ethylenediaminomonoacet\$ or taurodihydrofusidate or (sodium salicylate) or (sodium caprate) or (sodium glycocholate) cholsarcosine or (isopropyl myristate))	607
<input type="checkbox"/>	L3	L2 and ((calcium ion chelator) or surfactant or receptor)	727
<input type="checkbox"/>	L2	L1 and permeabilit\$	924
<input type="checkbox"/>	L1	stent and coat\$	8506

END OF SEARCH HISTORY

## WEST Search History





DATE: Wednesday, March 31, 2004

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L20	L19 and ((cell membrane?) or (membrane junction?) or (cell junction?))	29
<input type="checkbox"/>	L19	L18 and (actinomycin\$ or dactinomycin or (WI 53233) or Cosmegen)	29
<input type="checkbox"/>	L18	L17 and (EDDA or EDTA or IDA or NTA or EDMA)	38
<input type="checkbox"/>	L17	L16 and catheter	64
<input type="checkbox"/>	L16	L15 and (percutaneous\$ or transdermal\$)	66
<input type="checkbox"/>	L15	L14 and (permeation enhanc\$)	89
<input type="checkbox"/>	L14	L13 and endothelia\$	92
<input type="checkbox"/>	L13	L12 and (balloon or infusion)	101
<input type="checkbox"/>	L12	L11 and (polycaprolact\$ or polysiloxane? or (ethylene vinyl alcohol) or polyhydroxyvaler\$ polylact\$ or polyhydroxybutyr\$ or polydioxanone)	106
<input type="checkbox"/>	L11	L10 and (morpholinosydnonimine or (acetyl penicillamine) or VEGF or (endothelial growth factor))	111
<input type="checkbox"/>	L10	L9 and ((hydrolyzed triglyceride?) or (fatty acid suga) or olei\$ or histamine? bradykinin\$ or (TNF alpha) or (tumor necrosis factor alpha) nitroglycerine or (sodium nitroprusside) or (diethylamine sodium))	111
<input type="checkbox"/>	L9	L8 and ((membrane junctions) or (cell membrane?))	111
<input type="checkbox"/>	L8	L7 and expand\$	113
<input type="checkbox"/>	L7	L6 and (drug delivery)	163
<input type="checkbox"/>	L6	L5 and ((pluronic p 85) or verapamil or disulfiram or (antisense oligonucleotide?))	165
<input type="checkbox"/>	L5	L4 and (p glycoprotein) and blocker	169
<input type="checkbox"/>	L4	L3 and (iminodiacet\$ or nitriloacet\$ or ethylenediaminomonoacet\$ or taurodihydrofusidate or (sodium salicylate) or (sodium caprate) or (sodium glycocholate) cholysarcosine or (isopropyl myristate))	607
<input type="checkbox"/>	L3	L2 and ((calcium ion chelator) or surfactant or receptor)	727
<input type="checkbox"/>	L2	L1 and permeabilit\$	924
<input type="checkbox"/>	L1	stent and coat\$	8506

END OF SEARCH HISTORY

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:59:26 ON 31 MAR 2004

=> file caplus uspatful europatful japio medline biosis embase		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 17:59:53 ON 31 MAR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:59:53 ON 31 MAR 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 17:59:53 ON 31 MAR 2004  
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 17:59:53 ON 31 MAR 2004  
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 17:59:53 ON 31 MAR 2004

FILE 'BIOSIS' ENTERED AT 17:59:53 ON 31 MAR 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 17:59:53 ON 31 MAR 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> stent or catheter  
STENT IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s stent or catheter  
L1 287791 STENT OR CATHETER

=> s l1 and glucose  
L2 11765 L1 AND GLUCOSE

=> s l2 and ((cell membrane) or (cell junction#) or (membrane junction#))  
L3 2063 L2 AND ((CELL MEMBRANE) OR (CELL JUNCTION#) OR (MEMBRANE JUNCTI  
ON#))

=> s l3 and (permeabilizing agent)  
L4 2 L3 AND (PERMEABILIZING AGENT)

=> d l4 1-2 ibib abs

L4 ANSWER 1 OF 2 USPATFULL on STN  
ACCESSION NUMBER: 2004:34026 USPATFULL  
TITLE: HMG CoA reductase inhibitors for promoting angiogenesis  
INVENTOR(S): Walsh, Kenneth, Carlisle, MA, United States  
PATENT ASSIGNEE(S): Caritas St. Elizabeth's Medical Center of Boston, Inc.,

Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6689807	B1	20040210
APPLICATION INFO.:	US 2000-590740		20000608 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Weber, Jon P.		
LEGAL REPRESENTATIVE:	Edwards & Angell, LLP, Conlin, David G., Rees, Dianne M.		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 9 Drawing Page(s)		
LINE COUNT:	2179		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods and compositions for the treatment of conditions associated with vascular insufficiency, and to methods and compositions for screening assays to select agents that are useful for this purpose. In particular the invention relates to HMG CoA reductase inhibitors and their use in promoting angiogenesis in vivo and in activating Akt in vascular endothelial cells in vitro and in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2003:166524 USPATFULL  
TITLE: Glycogen synthase kinase function in endothelial cells  
INVENTOR(S): Walsh, Kenneth, Carlisle, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003114382	A1	20030619
APPLICATION INFO.:	US 2002-278759	A1	20021023 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-350160P	20011029 (60)
	US 2001-337905P	20011113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	3426	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods and compositions for modulating endothelial cell viability, endothelial cell migration, and angiogenesis. In particular the invention relates to GSK3 molecules, agents that modify the kinase activity of these molecules, and use of the foregoing in modulating the endothelial cell viability, endothelial cell migration, and angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> SET NOTICE DISPLAY 1

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND  
SET COMMAND COMPLETED

=> set auhelp off; set smart off; set msteps off; set expand cont; set audit off;  
del sel y

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

SET COMMAND COMPLETED

=> FILE CAPLUS,WPINDEX

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.88	31.09

FILE 'CAPLUS' ENTERED AT 18:03:38 ON 31 MAR 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Mar 2004 VOL 140 ISS 14  
FILE LAST UPDATED: 30 Mar 2004 (20040330/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S US 2003114382/PN,APPS

1 US 2003114382/PN  
(US2003114382/PN)  
0 US 2003114382/AP  
0 US 2003114382/PRN  
0 US 2003114382/APPS  
(US 2003114382/AP,PRN)  
L5 1 US 2003114382/PN,APPS

=> FILE INPADOC

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.89	36.98

FILE 'INPADOC' ENTERED AT 18:03:43 ON 31 MAR 2004  
COPYRIGHT (C) 2004 European Patent Office, Vienna (EPO)

FILE LAST UPDATED: 25 MAR 2004 <20040325/UP>  
25 MAR 2004 <20040325/UPLS>  
MOST RECENT INPADOC WEEK: 200413 <200413/EW>  
FILE COVERS 1968 TO DATE.

LEGAL STATUS REBUILD ---> SEE NEWS OR  
<http://www.stn-international.de/stndatabases/details/LSR.pdf>

>>> FOR STATISTIC OF CURRENT WEEK'S NEW ENTRIES,  
ENTER HELP UPS <<<

>>> STATISTIC FOR UPDATES OF PUBLICATION/PATENT KIND CODES  
A. SORTED BY COUNTRY:  
<http://www.stn-international.de/stndatabases/details/inpadoc/fkd1>  
B. SORTED BY DATE:  
<http://www.stn-international.de/stndatabases/details/inpadoc/fkd2>

<<<

>>> THE BASIC INDEX NOW CONTAINS SINGLE TERMS FROM THE  
TITLE (/TI) AND ABSTRACT FIELDS (/AB) AND ALLOWS  
SIMULTANEOUS LEFT AND RIGHT TRUNCATION (SLART) <<<

>>> FOR CHANGES IN INPADOC ---> SEE HELP CHANGE  
(LAST UPDATED FEB 3, 2004) <<<

=> TRA L5 PN

L6 TRANSFER L5 1- PN : 3 TERMS  
L7 3 L6

=>

=> S L7 AND US/PC

3808724 US/PC  
L8 1 L7 AND US/PC

=> SEL PN

E1 THROUGH E1 ASSIGNED

=> S L7 AND ZA/PC

193467 ZA/PC  
L9 0 L7 AND ZA/PC

=> SEL PN

L9 HAS NO ANSWERS

=> S L7 AND EP/PC AND EN/LA

1402655 EP/PC  
2235996 EN/LA  
L10 0 L7 AND EP/PC AND EN/LA

=> SEL PN

L10 HAS NO ANSWERS

=> S L7 AND WO/PC AND EN/LA

848705 WO/PC  
2235996 EN/LA

L11 1 L7 AND WO/PC AND EN/LA

=> SEL PN

E2 THROUGH E2 ASSIGNED

=> S L7 AND CA/PC AND EN/LA

855845 CA/PC  
2235996 EN/LA

L12 0 L7 AND CA/PC AND EN/LA

=> SEL PN

L12 HAS NO ANSWERS

=> D SELECT

E1	1	US2003114382/PN
E2	2	WO2003038037/PN

=>

Do you want to retrieve bibliographic & abstract data for these patent numbers from the CAPLUS and WPINDEX files (Y/N)?

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND  
SET COMMAND COMPLETED